Panitumumab Infusion Recalled Due to Lack of Sterility Assurance
Infusion Options, Inc. is recalling Panitumumab 400 mg/100 mL IV products in New York due to a lack of assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a 'Severe' rating under the rubric, particularly given the risk of infection from lack of sterility assurance.
Plain-English summary
Infusion Options, Inc. is recalling Panitumumab 400 mg / 100 mL NS IVPB, a prescription-only intravenous infusion product. The recall is being conducted because of a lack of assurance of sterility. The affected products are distributed in New York only, and all lots within the expiration date are included in this recall.
This recall is classified as FDA Class II, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The specific hazard identified is the lack of assurance of sterility, which poses a risk of infection or other adverse health effects if the product is not sterile.
Patients who have received this product should contact their healthcare provider for guidance. Healthcare providers should stop using the recalled product and contact Infusion Options, Inc. for further instructions. Consumers should not use the product if they have it in their possession.
The recalled product
- Product
- PANITUMUMAB 400 MG / 100 ml NS IVPB, Rx Only, Infusion Options, Inc. 5924 13the Ave, Brooklyn, NY 11219-4934, 718-283-7233
- Manufacturer
- Infusion Options, Inc.
- Category
- Drug — Biologic / Infusion
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 76 recalled by Infusion Options, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 76 products in this recall →Related recalls
Same manufacturer · Infusion Options, Inc.
See all →- SevereInfusion Options Recalls Calcium Glucunate IV Bags Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Durvalumab Infusions Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Rituximab Infusions Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Fluorouracil Infusions Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
- SevereInfusion Options Recalls Velcade Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-08-21
Same hazard · lack of sterility
See all →- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
Similar recalls
- HighVancomycin Intravenous Solution Recalled Due to Sterility Assurance Issue
FDA (Drugs) · 2023-02-22
- SevereFentanyl Infusion Solution Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2022-03-23
- HighVancomycin Injectable Bags Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2023-02-22
- HighFentanyl Injectable Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-08-09
- HighFDA Recalls Fentanyl Injectable for Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- SevereAssurance Infusion Recalls Buprenorphine and Fentanyl Injection Due to Sterility Concerns
FDA (Drugs) · 2020-01-22